GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » Gross Profit

Walvax Biotechnology Co (SZSE:300142) Gross Profit : ¥3,294 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co Gross Profit?

Walvax Biotechnology Co's gross profit for the three months ended in Mar. 2024 was ¥486 Mil. Walvax Biotechnology Co's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was ¥3,294 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Walvax Biotechnology Co's gross profit for the three months ended in Mar. 2024 was ¥486 Mil. Walvax Biotechnology Co's Revenue for the three months ended in Mar. 2024 was ¥600 Mil. Therefore, Walvax Biotechnology Co's Gross Margin % for the quarter that ended in Mar. 2024 was 81.07%.

Walvax Biotechnology Co had a gross margin of 81.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Walvax Biotechnology Co was 88.61%. The lowest was 42.85%. And the median was 80.07%.


Walvax Biotechnology Co Gross Profit Historical Data

The historical data trend for Walvax Biotechnology Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co Gross Profit Chart

Walvax Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 894.12 2,539.21 3,068.49 4,476.98 3,516.22

Walvax Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 708.42 1,186.68 811.68 809.44 486.24

Competitive Comparison of Walvax Biotechnology Co's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's Gross Profit falls into.



Walvax Biotechnology Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Walvax Biotechnology Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=4113.772 - 597.556
=3,516

Walvax Biotechnology Co's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=599.754 - 113.519
=486

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,294 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Walvax Biotechnology Co's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=486 / 599.754
=81.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Walvax Biotechnology Co  (SZSE:300142) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Walvax Biotechnology Co had a gross margin of 81.07% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Walvax Biotechnology Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co (SZSE:300142) Business Description

Traded in Other Exchanges
N/A
Address
Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Executives
Wu Yun Yan Executives
Zhao Jin Long Executives
Yao Wei Executives
Zhou Hua Executives
Shi Jing Executives
Jiang Run Sheng Directors, executives
Gong Sun Qing Executives
Executives
Yuan Lin Executives
Fang Guo Liang Executives
Li Yun Chun Director
Huang Zhen Director
Zhang Li Secretary Dong
Yang Hong Wei Supervisors
Xu Ke Ren Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines